David  Shan net worth and biography

David Shan Biography and Net Worth

David Shan serves as executive vice president and chief integrated supply chain officer. Shan has global responsibility for the leadership of the Supply Chain; Operations; Procurement; Lean & Operational Excellence; and the Environmental, Health & Safety and Sustainability teams across the company. He is also a member of the BD Executive Leadership Team.

Shan most recently served as executive vice president and chief quality officer, where he played an important role in the efforts to simplify the organization and advance BD’s culture of quality to continually strengthen processes and ensure BD products and services are safe, reliable and effective.

Shan joined BD in 2015 and has continued to advance his career and learning by rotating across multiple functions and businesses. He first served as vice president of global operations for the Pharmaceutical Systems business, before taking on expanded responsibility leading operations for several of BD’s devices businesses. He also served as senior vice president of global supply chain, where he strengthened the function to be more agile and customer focused, adding new systems and technologies, optimizing the distribution and logistics network and improving delivery time to customers.

Before joining BD, Shan served as chief operating officer for SGD Pharma, overseeing quality, manufacturing operations, R&D and supply chain, among other functions. He previously led global quality and operational excellence for Graham Packaging, where he integrated and deployed a single global Quality Management System and delivered significant reductions in customer complaints. He began his career at 3M, where he received his Six Sigma Black Belt certification and held multiple positions including technical services and plant quality manager.

Shan holds a master’s degree in Material Sciences from Ecole Nationale d’Ingenieurs de Tarbes in France and an Executive MBA from ESSEC Business School in Paris, France.

What is David Shan's net worth?

The estimated net worth of David Shan is at least $886.09 thousand as of June 2nd, 2025. Mr. Shan owns 4,575 shares of Becton, Dickinson and Company stock worth more than $886,091 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Shan may own. Learn More about David Shan's net worth.

How do I contact David Shan?

The corporate mailing address for Mr. Shan and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on David Shan's contact information.

Has David Shan been buying or selling shares of Becton, Dickinson and Company?

David Shan has not been actively trading shares of Becton, Dickinson and Company in the last ninety days. Most recently, David Shan sold 1,166 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a transaction totalling $199,607.54. Following the completion of the sale, the executive vice president now directly owns 4,575 shares of the company's stock, valued at $783,194.25. Learn More on David Shan's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Richard Byrd (EVP and President, Interventional Segment ), Richard Byrd (EVP), Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Michael Feld (Executive Vice President and President, Life Sciences), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), Jeffrey Henderson (Director), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Shana Neal (EVP and Chief People Officer), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), Bertram Scott (Director), David Shan (EVP), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, Becton, Dickinson and Company insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $350,430.00. During the last year, insiders at the medical instruments supplier sold shares 18 times. They sold a total of 17,960 shares worth more than $3,831,767.26. The most recent insider tranaction occured on December, 1st when EVP Michael Feld sold 75 shares worth more than $14,502.00. Insiders at Becton, Dickinson and Company own 0.4% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 12/1/2025.

David Shan Insider Trading History at Becton, Dickinson and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2025Sell1,166$171.19$199,607.544,575View SEC Filing Icon  
1/21/2025Sell500$240.00$120,000.005,741View SEC Filing Icon  
See Full Table

David Shan Buying and Selling Activity at Becton, Dickinson and Company

This chart shows David Shan's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $193.68
Low: $192.09
High: $194.10

50 Day Range

MA: $188.09
Low: $176.22
High: $195.48

2 Week Range

Now: $193.68
Low: $162.29
High: $251.99

Volume

1,253,147 shs

Average Volume

2,412,403 shs

Market Capitalization

$55.28 billion

P/E Ratio

33.22

Dividend Yield

2.15%

Beta

0.25